Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in two upcoming investor conferences, focusing on improving survival and quality of life for patients with unmet medical needs. The Craig-Hallum Alpha Select Virtual Conference will occur on November 17, 2020, while the Benchmark Annual Discovery 1x1 Investor Virtual Conference takes place on November 18, 2020. Interested parties can schedule one-on-one meetings with management through conference representatives. Processa's active pipeline includes treatments for metastatic colorectal cancer, breast cancer, and gastroparesis.
- None.
- None.
Insights
Analyzing...
Processa’s pipeline includes several clinical-stage drug candidates
HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:
Craig-Hallum Alpha Select Virtual Conference
- Tuesday, Nov. 17, 2020 (one-on-one meetings only)
Benchmark Annual Discovery 1x1 Investor Virtual Conference
- Wednesday, Nov. 18, 2020 (one-on-one meetings only)
To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
FAQ
When is Processa Pharmaceuticals participating in conferences in November 2020?
How can I schedule a meeting with Processa Pharmaceuticals management during the conferences?
What is the mission of Processa Pharmaceuticals?
What drugs are in Processa Pharmaceuticals' pipeline?
What is the stock symbol for Processa Pharmaceuticals?
